quinta-feira, 29 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· October 22, 2026

JAKKS outlines 2027 slate with Sonic the Hedgehog 4 in March as Toys 'R' Us opens 120 stores

View original at seekingalpha.com

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Not supporting new Q4 entertainment is a matter of timing. Private label has grown immensely, and Disney Princess and Frozen have seen tremendous growth.

    60% confidence
  • The 2027 content slate includes Sonic the Hedgehog 4 in March, the new Simpsons movie in September and Frozen 3 in November.

    60% confidence
  • In 2024 the back half had meaningful entertainment tentpoles, including Moana 2 and a Sonic 3 movie. Current-quarter strength came from evergreen growth.

    60% confidence
  • The main international opportunities are EMEA, then Latin America and Southeast Asia. JAKKS is building warehouses and distribution centers in Italy, Spain, Germany, the U.K. and Rotterdam, and expanding licensed rights in new territories.

    60% confidence
  • Toys "R" Us is being licensed out, with about 120 stores opening this year. JAKKS is selling into them and hopes they become full-time year-round stores.

    60% confidence
  • Some Q4 sales moved into Q3 this year, which is normal for an FOB-centric business and means JAKKS gets paid sooner.

    60% confidence
  • JAKKS is acquiring licenses and remains a kid-centric business, while also participating in kidult and adult collectibles including anime.

    60% confidence
  • Gross margin was 32.1%, adjusted EBITDA $44.4 million and adjusted EPS $2.68. Cash was $45 million (restricted and unrestricted) and inventory $64 million.

    60% confidence
  • The Board approved a quarterly cash dividend of $0.25 per share, payable to holders of record as of November 27 and paid on December 28.

    60% confidence
  • Factories face higher resin prices and the supply chain faces higher diesel prices. JAKKS is prioritizing shipments and scrutinizing inventory to mitigate the costs.

    60% confidence
  • JAKKS is done with tariff refunds.

    60% confidence
  • JAKKS is heading into year-end with solid momentum and Berman is extremely confident. No numeric guidance was given.

    60% confidence
  • JAKKS is launching a long-term strategic initiative on immersive IP across anime, manga, VTubers and digital entertainers. Partners and titles debuting next year are best-in-class, and retail and customer feedback has been very enthusiastic.

    60% confidence
  • The U.S. tariff discussion appears to be trending favorably, but definitive guidance is still pending.

    60% confidence
  • The Disney Princess and Disney Frozen business is exceeding expectations more than anything else in the 2026 portfolio.

    60% confidence
  • JAKKS is not supporting any new entertainment releases in toys this holiday season. North America grew 28%, Dolls and Role Play/Dress-Up grew 29%, and Action Play & Collectibles grew 19% in the quarter.

    60% confidence
  • International is about 85-90% FOB. JAKKS is building domestic capabilities as backup inventory for Europe lead times.

    60% confidence
  • International margins are comparable to the U.S. JAKKS is going much deeper than a few mass accounts into multiple channels and making nice margins.

    60% confidence
  • The FOB business model represents over 75% of sales for the first 9 months, and buying patterns are returning to pre-tariff quarterly seasonality.

    60% confidence
  • Q3 shipping generated $254 million in net sales, up 20%. Year-to-date sales are up 13%.

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,994
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,994 factos verificados com a fonte5,503 documentos-fonte arquivados
Consulte estes dados → isubstrate.com